Published in Sex Transm Dis on October 01, 2002
Vaginal microbicides: detecting toxicities in vivo that paradoxically increase pathogen transmission. BMC Infect Dis (2006) 2.01
Mouse model of cervicovaginal toxicity and inflammation for preclinical evaluation of topical vaginal microbicides. Antimicrob Agents Chemother (2004) 1.50
High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis (2009) 1.38
Vaginal microbicide gel for delivery of IQP-0528, a pyrimidinedione analog with a dual mechanism of action against HIV-1. Antimicrob Agents Chemother (2011) 1.25
Quantification of poly(I:C)-mediated protection against genital herpes simplex virus type 2 infection. J Virol (2006) 1.04
Water dispersible microbicidal cellulose acetate phthalate film. BMC Infect Dis (2003) 1.04
Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother (2005) 0.97
Antibody and antiretroviral preexposure prophylaxis prevent cervicovaginal HIV-1 infection in a transgenic mouse model. J Virol (2013) 0.84
Increased CCL2 expression and macrophage/monocyte migration during microbicide-induced vaginal irritation. Curr HIV Res (2009) 0.83
Nanoparticle transport from mouse vagina to adjacent lymph nodes. PLoS One (2012) 0.82
New candidate biomarkers in the female genital tract to evaluate microbicide toxicity. PLoS One (2014) 0.81
L-selectin and P-selectin are novel biomarkers of cervicovaginal inflammation for preclinical mucosal safety assessment of anti-HIV-1 microbicide. Antimicrob Agents Chemother (2012) 0.80
Infertility as a consequence of spermagglutinating Staphylococcus aureus colonization in genital tract of female mice. PLoS One (2012) 0.78
Multiple effects of silymarin on the hepatitis C virus lifecycle. Hepatology (2010) 1.92
PSI-7851, a pronucleotide of beta-D-2'-deoxy-2'-fluoro-2'-C-methyluridine monophosphate, is a potent and pan-genotype inhibitor of hepatitis C virus replication. Antimicrob Agents Chemother (2010) 1.84
Human monoclonal anti-protective antigen antibody completely protects rabbits and is synergistic with ciprofloxacin in protecting mice and guinea pigs against inhalation anthrax. Infect Immun (2006) 1.59
Mutations conferring resistance to SCH6, a novel hepatitis C virus NS3/4A protease inhibitor. Reduced RNA replication fitness and partial rescue by second-site mutations. J Biol Chem (2005) 1.54
Construction and evaluation of a chimeric pseudoinfectious virus vaccine to prevent Japanese encephalitis. Vaccine (2008) 1.54
Use of complementary and alternative medicine for the treatment of genital herpes. Herpes (2005) 1.48
High resolution imaging of epithelial injury in the sheep cervicovaginal tract: a promising model for testing safety of candidate microbicides. Sex Transm Dis (2009) 1.38
Human monoclonal antibody AVP-21D9 to protective antigen reduces dissemination of the Bacillus anthracis Ames strain from the lungs in a rabbit model. Infect Immun (2007) 1.37
Activity and the metabolic activation pathway of the potent and selective hepatitis C virus pronucleotide inhibitor PSI-353661. Antiviral Res (2011) 1.35
Herpes simplex virus (HSV) type 2 glycoprotein D subunit vaccines and protection against genital HSV-1 or HSV-2 disease in guinea pigs. J Infect Dis (2003) 1.28
miR-122 does not modulate the elongation phase of hepatitis C virus RNA synthesis in isolated replicase complexes. Antiviral Res (2010) 1.25
Protection against congenital cytomegalovirus infection and disease in guinea pigs, conferred by a purified recombinant glycoprotein B vaccine. J Infect Dis (2004) 1.25
Use of immunostimulatory sequence-containing oligonucleotides as topical therapy for genital herpes simplex virus type 2 infection. J Virol (2002) 1.19
Randomized controlled trial of an adjuvanted human papillomavirus (HPV) type 6 L2E7 vaccine: infection of external anogenital warts with multiple HPV types and failure of therapeutic vaccination. J Infect Dis (2005) 1.17
Safety and immunogenicity of glycoprotein D-adjuvant genital herpes vaccine. Clin Infect Dis (2005) 1.16
The fibroblast growth factor 14·voltage-gated sodium channel complex is a new target of glycogen synthase kinase 3 (GSK3). J Biol Chem (2013) 1.14
Application of optical coherence tomography for monitoring changes in cervicovaginal epithelial morphology in macaques: potential for assessment of microbicide safety. Sex Transm Dis (2008) 1.13
Preconception vaccination with a glycoprotein B (gB) DNA vaccine protects against cytomegalovirus (CMV) transmission in the guinea pig model of congenital CMV infection. J Infect Dis (2003) 1.13
Mutations in West Nile virus nonstructural proteins that facilitate replicon persistence in vitro attenuate virus replication in vitro and in vivo. Virology (2007) 1.11
Construction and characterization of a second-generation pseudoinfectious West Nile virus vaccine propagated using a new cultivation system. Vaccine (2008) 1.09
Impact of immunization with glycoprotein D2/AS04 on herpes simplex virus type 2 shedding into the genital tract in guinea pigs that become infected. J Infect Dis (2005) 1.08
Antiviral suppression vs restoration of RIG-I signaling by hepatitis C protease and polymerase inhibitors. Gastroenterology (2008) 1.07
VivaGel (SPL7013 Gel): a candidate dendrimer--microbicide for the prevention of HIV and HSV infection. Int J Nanomedicine (2007) 1.04
Novel imino sugar derivatives demonstrate potent antiviral activity against flaviviruses. Antimicrob Agents Chemother (2009) 1.04
Parental acceptance of adolescent vaccines within school-based health centres. Herpes (2005) 1.04
Antiviral profiles of novel iminocyclitol compounds against bovine viral diarrhea virus, West Nile virus, dengue virus and hepatitis B virus. Antivir Chem Chemother (2007) 1.00
Molecular mechanisms underlying inner ear patterning defects in kreisler mutants. Dev Biol (2005) 1.00
Perceptions of reimbursement for clinical trial participation. J Empir Res Hum Res Ethics (2011) 0.98
Efficacy and toxicity of zinc salts as candidate topical microbicides against vaginal herpes simplex virus type 2 infection. Antimicrob Agents Chemother (2005) 0.97
Inhibition of hepatitis C virus replicon RNA synthesis by PSI-352938, a cyclic phosphate prodrug of β-D-2'-deoxy-2'-α-fluoro-2'-β-C-methylguanosine. Antimicrob Agents Chemother (2011) 0.95
A Vaxfectin(®)-adjuvanted HSV-2 plasmid DNA vaccine is effective for prophylactic and therapeutic use in the guinea pig model of genital herpes. Vaccine (2012) 0.93
Evolution of a cell culture-derived genotype 1a hepatitis C virus (H77S.2) during persistent infection with chronic hepatitis in a chimpanzee. J Virol (2014) 0.93
Bioluminescence methodology for the detection of protein-protein interactions within the voltage-gated sodium channel macromolecular complex. Assay Drug Dev Technol (2012) 0.92
Current thinking on genital herpes. Curr Opin Infect Dis (2014) 0.92
Optical coherence tomography compared with colposcopy for assessment of vaginal epithelial damage: a randomized controlled trial. Obstet Gynecol (2011) 0.91
Factors predicting the acceptance of herpes simplex virus type 2 antibody testing among adolescents and young adults. Sex Transm Dis (2004) 0.91
Antibody-mediated protection against genital herpes simplex virus type 2 disease in mice by Fc gamma receptor-dependent and -independent mechanisms. J Reprod Immunol (2007) 0.91
Topical microbicide use by adolescent girls: concerns about timing, efficacy, and safety. Sex Transm Dis (2003) 0.90
Modification of primary and recurrent genital herpes in guinea pigs by passive immunization. J Gen Virol (2002) 0.90
Neonatal herpes should be a reportable disease. Sex Transm Dis (2005) 0.89
Is herpes simplex virus type 1 (HSV-1) now more common than HSV-2 in first episodes of genital herpes? Sex Transm Dis (2003) 0.88
Evaluation of RepliVAX WN, a single-cycle flavivirus vaccine, in a non-human primate model of West Nile virus infection. Am J Trop Med Hyg (2010) 0.88
Antiviral activity of geneticin against dengue virus. Antiviral Res (2009) 0.88
Discovery of small molecule inhibitors of West Nile virus using a high-throughput sub-genomic replicon screen. Antiviral Res (2006) 0.87
RepliVAX WN, a single-cycle flavivirus vaccine to prevent West Nile disease, elicits durable protective immunity in hamsters. Vaccine (2009) 0.87
Use of high-resolution confocal imaging of the vaginal epithelial microstructure to detect microbicide toxicity. J Infect Dis (2009) 0.87
New biomedical approaches for sexually transmitted infection prevention: vaccines and microbicides. Adolesc Med Clin (2004) 0.87
Adolescent issues associated with knowledge of and access to topical microbicides. J Womens Health (Larchmt) (2004) 0.86
Estradiol improves genital herpes vaccine efficacy in mice. Vaccine (2009) 0.85
Benzalkonium chloride causes colposcopic changes and increased susceptibility to genital herpes infection in mice. Sex Transm Dis (2010) 0.85
Seroprevalence of cytomegalovirus (CMV) and risk factors for infection in adolescent males. Clin Infect Dis (2010) 0.84
Enhancing the utility of a prM/E-expressing chimeric vaccine for Japanese encephalitis by addition of the JEV NS1 gene. Vaccine (2011) 0.83
Fibroblast growth factor 18 gives growth and directional cues to airway cartilage. Laryngoscope (2009) 0.83
Conjugation to nickel-chelating nanolipoprotein particles increases the potency and efficacy of subunit vaccines to prevent West Nile encephalitis. Bioconjug Chem (2010) 0.83
Prevention of mother-to-child transmission of viral infections. Curr Probl Pediatr Adolesc Health Care (2008) 0.83
Optical coherence tomography for assessment of microbicide safety in a small animal model. J Biomed Opt (2013) 0.83
Immunogenicity of RepliVAX WN, a novel single-cycle West Nile virus vaccine. Vaccine (2010) 0.82
Quantitative-competitive PCR monitoring of viral load following experimental guinea pig cytomegalovirus infection. J Virol Methods (2003) 0.82
Influence of methamphetamine on genital herpes simplex virus type 2 infection in a mouse model. Sex Transm Dis (2012) 0.82
Quantitative assessment of microbicide-induced injury in the ovine vaginal epithelium using confocal microendoscopy. BMC Infect Dis (2012) 0.82
Long-term presence of virus-specific plasma cells in sensory ganglia and spinal cord following intravaginal inoculation of herpes simplex virus type 2. J Virol (2005) 0.82
Monitoring vaginal epithelial thickness changes noninvasively in sheep using optical coherence tomography. Am J Obstet Gynecol (2013) 0.81
Image-based noninvasive evaluation of colorectal mucosal injury in sheep after topical application of microbicides. Sex Transm Dis (2013) 0.81
In vivo evaluation of antiviral efficacy against genital herpes using mouse and guinea pig models. Methods Mol Biol (2013) 0.80
Intrinsic adjuvanting of a novel single-cycle flavivirus vaccine in the absence of type I interferon receptor signaling. Vaccine (2012) 0.80
Acceptability of optical coherence tomography and abstinence requirements among women participating in microbicide safety trials. Sex Transm Dis (2012) 0.80
Genomic organization and expression analysis of the murine Fam3c gene. Gene (2004) 0.80
Pediatrics and herpes simplex virus vaccines. Semin Pediatr Infect Dis (2005) 0.79
Non-exclusivity in adolescent girls' romantic relationships. Sex Transm Dis (2003) 0.78
Parental acceptability of vaccines for sexually transmitted infections. Arch Pediatr Adolesc Med (2005) 0.78
Treatment with a novel topical nanoemulsion (NB-001) speeds time to healing of recurrent cold sores. J Drugs Dermatol (2012) 0.78
Development and utilization of a custom PCR array workflow: analysis of gene expression in mycoplasma genitalium and guinea pig (Cavia porcellus). Mol Biotechnol (2015) 0.78
3,4-Methylenedioxymethamphetamine increases susceptibility to genital herpes simplex virus infection in mice. J Infect Dis (2009) 0.77
Prevalence of herpes simplex virus types 1 and 2 among children and adolescents attending a sexual abuse clinic. Pediatr Infect Dis J (2006) 0.76
Effect of candidate vaginally-applied microbicide compounds on recognition of antigen by CD4+ and CD8+ T lymphocytes. Biol Reprod (2004) 0.76
An animal model of neonatal cytomegalovirus infection. Antiviral Res (2003) 0.76
Effects of candidate vaginally-applied microbicide compounds on innate immune cells. J Reprod Immunol (2005) 0.76
Estimating the population prevalence of HPV. JAMA (2007) 0.75
Screening for neonatal herpes: physicians' descriptions of discussions with parents. Herpes (2002) 0.75
Parental reasons for utilization of an urban pediatric emergency department during the 2009 H1N1 influenza epidemic. Pediatr Emerg Care (2011) 0.75
The relationship between STD locus of control and STD acquisition among adolescent girls. Adolescence (2002) 0.75
A framework for faculty development. J Pediatr (2011) 0.75
Predictors of herpes simplex virus type 2 antibody positivity among persons with no history of genital herpes. Sex Transm Dis (2004) 0.75
Vaccines for sexually transmitted infections. Pediatr Ann (2005) 0.75
Reducing the stigma of herpes simplex virus infection: lessons from an online video contest. Sex Health (2012) 0.75